Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder

Pharmacotherapy

Volumn 24, Issue 8, 2004, Pages 1020-1036

  Christman, Alisa K ^a   Fermo, Joli D ^a   Markowitz, John S ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Atomoxetine; Attention deficit hyperactivity disorder; Pharmacokinetics

Indexed keywords

ATOMOXETINE; FLUOXETINE; METHYLPHENIDATE; PAROXETINE; PLACEBO; PSYCHOSTIMULANT AGENT;

ABDOMINAL PAIN; APPETITE DISORDER; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DOSE RESPONSE; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSMENORRHEA; DYSPEPSIA; DYSURIA; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; IMPOTENCE; INSOMNIA; LIBIDO DISORDER; MOOD DISORDER; NAUSEA; NEUROTOXICITY; NORADRENERGIC SYSTEM; PRESYNAPTIC NERVE; RELAPSE; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; TREATMENT OUTCOME; URINE RETENTION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ADULT; ANIMALS; AREA UNDER CURVE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; FEMALE; HALF-LIFE; HUMANS; INTESTINAL ABSORPTION; MALE; PREGNANCY; PROPYLAMINES; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 3543123450     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.11.1020.36146     Document Type: Review

References (38)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 2000.
2. Wender FH, Wolf LE, Wasserstein J. Adults with attention-deficit/ hyperactivity disorder: an overview. Ann NY Acad Sci 2001;931:1-16.
3. Spencer TJ, Biederman J, Wilens TE, Faraone SV. Overview and neurobiology of attention-deficit/hyperactivity disorder. J Clin Psychiatry 2003;63(suppl 12):3-9.
4. Wilens TE, Biederman J, Spencer TJ, Prince J. Pharmacotherapy of adult attention-deficit/hyperactivity disorder: a review. J Clin Psychopharmacol 1995;15:270-8.
5. Barkley RA. Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002;63(suppl 2):10-15.
6. Spencer T, Biederman J, Wilens T, et al. Effectiveness and tolerability of tomoxetine in adults with attention-deficit/hyperactivity disorder. Am J Psychiatry 1998;155:693-5.
7. Adler LA, Chua HC. Management of ADHD in adults. J Clin Psychiatry 2003;63(suppl 2):29-35.
8. Spencer TJ, Biederman J, Wilens TE, Faraone SV. Novel treatments for attention-deficit/hyperactivity disorder in children. J Clin Psychiatry 2002;63 (suppl 12):16-22.
9. Biederman J, Spencer T. Non-stimulant treatments for ADHD. Eur Child Adolesc Psychiatry 2000;9(suppl 1):51-9.
10. Barr CL, Kroft J, Feng Y, et al. The norepinephrine transporter gene and attention-deficit/hyperactivity disorder. Am J Med Genet 2002;114:255-9.
11. Findling RL, Schwartz MA, Flannery DJ, Manos MJ. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. J Clin Psychiatry 1996; 57:184-9.
12. Wilens TE, Biederman J, Spencer TJ, et al. A controlled clinical trial of buproprion for attention-deficit/hyperactivity disorder in adults. Am J Psychiatry 2001;158:282-8.
13. Berridge CW, Arnsten AF, Foote SL. Noradrenergic modulation of cognitive function: clinical implications of anatomical electrophysiological and behavioral studies in animal models. Psychol Med 1993;23:557-64.
14. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002;27:699-711.
15. Fuller R, Wong DT. Effects of antidepressants on uptake and receptor systems in the brain. Prog Neuropsychopharmacol Biol Psychiatry 1985;9:485-90.
16. Eli Lilly and Company. Strattera (atomoxetine) package insert. Indianapolis, IN; 2002.
17. Chalon SA, Desager JP, DeSante KA, et al. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and metabolites. Clin Pharmacol Ther 2003;73:178-91.
18. Witcher J, Long A, Smith B, et al. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2003;13:53-63.
19. Sauer JM, Ponsler GD, Mattiuz EL, et al. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos 2003;31:98-107.
20. Farid NA, Bergstrom RF, Ziege EA, Parli GJ, Lemberger L. Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. J Clin Pharmacol 1985;25:296-301.
21. Guengerich FP. Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, ed. Cytochrome P450: structure, mechanism, and biochemistry. New York: Plenum Press, 1995:473-535.
22. Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos 2002;30:319-23.
23. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2002;108:1-9.
24. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention-deficit hyperactivity disorder: a randomized, placebo-controlled study Am J Psychiatry 2002;159:1896-901.
25. Spencer T, Heilgenstein JH, Biederman J, et al. Results from two proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002;63:1140-7.
26. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002;41:776-84.
27. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with attention-deficit/hyperactivity disorder: two randomized, placebo-controlled studies. Biol Psychiatry 2003;53:112-20.
28. Kelsey D, Sumner C, Sutton V, Malcom S, Schuh K. Once-daily atomoxetine in childhood ADHD: continuous symptom relief. Presented at the 156th annual meeting of the American Psychiatric Association, San Francisco, CA, May 17-22, 2003.
29. Newcorn J, Michelson D, Spencer T, Milton D. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder. Presented at the 49th annual meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco, CA, October 22-27, 2002.
30. Heiligenstein JH, Dunn D, Busher J, Stein M, McDougle CJ. Efficacy of atomoxetine vs placebo in school-aged children with attention-deficit/ hyperactivity disorder who failed treatment with a psychostimulant. Presented at the 154th annual meeting of the American Psychiatric Association, New Orleans, LA, November 5-10, 2001.
31. Heiligenstein J, Wagner K, Casat C, et al. Efficacy of atomoxetine vs placebo in school-aged children of the inattentive type. Presented at the 154th annual meeting of the American Psychiatric Association, New Orleans, LA, November 5-10, 2001.
32. Biederman J, Heiligenstein JH, Faries D, et al. Efficacy of atomoxetine vs placebo in school-aged girls with attention-deficit/hyperactivity disorder [online exclusive article]. Pediatrics 2002;110(6):e75. Available from www.Pediatrics. org.
33. Allen AJ, Wernicke J, Dunn D, et al. Safety and efficacy of atomoxetine in pediatric CYP2D6 extensive versus poor metabolizers. Presented at the 57th annual meeting of the Society of Biological Psychiatry, Philadelphia, PA, May 16-18, 2002.
34. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 2002;63(suppl 12):50-5.
35. Sauer JM, Long AJ, Ring B, et al. Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome. J Pharmacol Exp Ther 2004;308:410-18.
36. Belle DJ, Ernest S, Sauer JM, et al. Effect of CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol 2002;42:1219-27.
37. Patrick KS, Markowitz JS. Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder. Hum Psychopharmacol 1997;12:527-46.
38. Heil SH, Holmes HW, Bickel WK, et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 2002;67:149-56.